drugset / Trial / NCT05075304
A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 Patients
Phase 1
Terminated
18 enrolled
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Beijing Defengrui Biotechnology Co. Ltd · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This open, multi-center, multiple ascending dose study was designed to evaluate the safety, tolerability, preliminary efficacy and PK/PD of BDB-001 injection in patients with mild, or general COVID-19.
Timeline
- Start
- 2020-02-21
- Primary completion
- 2020-04-14
- Completion
- 2020-04-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Resiquimod | Small molecule | — | Intravenous |